- Home
- CCCC vs ACIU Comparison
CCCC vs ACIU Comparison
Compare CCCC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- ACIU
- Stock Information
- Founded
- CCCC 2015
- ACIU 2003
- Country
- CCCC United States
- ACIU Switzerland
- Employees
- CCCC N/A
- ACIU N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- CCCC Health Care
- ACIU Health Care
- Exchange
- CCCC Nasdaq
- ACIU Nasdaq
- Market Cap
- CCCC 244.9M
- ACIU 247.4M
- IPO Year
- CCCC 2020
- ACIU 2016
- Fundamental
- Price
- CCCC $1.52
- ACIU $1.88
- Analyst Decision
- CCCC Buy
- ACIU Strong Buy
- Analyst Count
- CCCC 4
- ACIU 2
- Target Price
- CCCC $12.50
- ACIU $12.00
- AVG Volume (30 Days)
- CCCC 777.7K
- ACIU 187.3K
- Earning Date
- CCCC 05-07-2025
- ACIU 03-13-2025
- Dividend Yield
- CCCC N/A
- ACIU N/A
- EPS Growth
- CCCC N/A
- ACIU N/A
- EPS
- CCCC N/A
- ACIU N/A
- Revenue
- CCCC $35,584,000.00
- ACIU $30,136,397.00
- Revenue This Year
- CCCC N/A
- ACIU $120.91
- Revenue Next Year
- CCCC $36.32
- ACIU $13.82
- P/E Ratio
- CCCC N/A
- ACIU N/A
- Revenue Growth
- CCCC 71.44
- ACIU 84.51
- 52 Week Low
- CCCC $1.39
- ACIU $1.77
- 52 Week High
- CCCC $8.08
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- CCCC 25.37
- ACIU 29.21
- Support Level
- CCCC $1.79
- ACIU $1.77
- Resistance Level
- CCCC $2.28
- ACIU $2.05
- Average True Range (ATR)
- CCCC 0.15
- ACIU 0.12
- MACD
- CCCC -0.02
- ACIU -0.02
- Stochastic Oscillator
- CCCC 14.61
- ACIU 18.71
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.